Initial Period: Disease Activity Score (DAS)28 (C-reactive Protein ) and DAS28 (Erythrocyte Sedimentation Rate )Įxtension Period: Change From Baseline in Disease Activity Score (DAS) 28-3 C-Reactive Protein (CRP)(DAS28-3 CRP) and DAS28-4 Erythrocyte Sedimentation Rate (ESR)(DAS28-4 ESR) at Month 3, 6, 9 and 12īaseline (Month 0 at the entry of Initial period) Month 3, 6, 9 and 12 of Extension Period Not applicable as no data were collected for this endpoint. Initial Period: Area Under American College of Rheumatology (ACR) n Curve Initial Period: Percentage of Patients With American College of Rheumatology (ACR) 20, 50, and 70 ResponsesĮxtension Period: Percentage of Participants With American College of Rheumatology (ACR) 20, 50, and 70 Responses

Includes AEs for every visit and up to 999 days after last dose of study drugĮxtension Period: Percentage of Participants With Adverse Events and Who Discontinued Treatment Due to Adverse Events to Assess Long-term Safety and Tolerability of Tofacitinibīaseline (Day 1 at Entry of Extension Period) up to Month 6 of Extension Period Month 6 of Extension Period to Month 12 of Extension Period Initial Period: The Long Term Safety and Tolerability of CP-690,550 5 Milligrams (mg) Twice Daily (BID) and 10 mg BID for the Treatment of Rheumatoid Arthritis

Includes laboratory test abnormality data for all visits and adverse event data up to 999 days after last dose of study drugĮxtension Period: Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs)īaseline (Day 1 at Entry of Extension Period) up to 28 days after last study drug dose in Extension Period (13 Months)Įxtension Period: Number of Participants With Laboratory Test Abnormalities Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports

Dr stefan kaiser virginia mason wa